Pricing & Access· August 22, 2026 · 17 min read
CMS's 340B OPPS Cut: ASP Minus 33.4%, the 2026 Survey, and August 31 Clock
By Ran Chen#340B#CMS#Medicare Part B
Topic
Buy and Bill
Buy-and-bill purchasing, provider-administered drug inventory risk, acquisition cost management, and specialty drug reimbursement.
Manufacturing· August 5, 2026 · 21 min read
2026 oncology injectable shortage: ifosfamide, carboplatin & buy-and-bill
By Ran Chen#Supply Chain#Oncology#Manufacturing
Approvals· July 28, 2026 · 23 min read
Lytenava & Wet AMD: First FDA-Approved Ophthalmic Bevacizumab and Buy-and-Bill
By Ran Chen#FDA Approval#Wet AMD#Anti-VEGF
Pricing & Access· July 18, 2026 · 18 min read
Sarclisa Escena SC access: CirCLIQ on-body injector, trial data, and billing
By Ran Chen#Oncology#FDA Approval#Specialty Pharmacy
Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Generics· June 22, 2026 · 19 min read
Generic Lanreotide Acetate: 505(b)(2) Approvals and Medical-Benefit Coding
By Ran Chen#Generics#FDA Approval#Orange Book
Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology
Manufacturing· June 14, 2026 · 11 min read
The oncology injectable shortage, in data: carboplatin and 18 chemo molecules
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization